362 related articles for article (PubMed ID: 36232447)
61. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
Amaador K; Vos JMI; Pals ST; Kraan W; Dobber JA; Minnema MC; Koene HR; de Bruin PC; Zwinderman AH; Kersten MJ
Leuk Lymphoma; 2022 May; 63(5):1070-1079. PubMed ID: 34961399
[TBL] [Abstract][Full Text] [Related]
62. Waldenstrom Macroglobulinemia Arising During Maintenance Therapy of Plasma Cell Myeloma.
Jin N; Ye P; Chen C; Xiao D
Clin Lab; 2023 Feb; 69(2):. PubMed ID: 36787553
[TBL] [Abstract][Full Text] [Related]
63. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia.
Issa GC; Leblebjian H; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2011 Jul; 18(4):260-5. PubMed ID: 21519243
[TBL] [Abstract][Full Text] [Related]
64. Clonally related transformation from Waldenström macroglobulinemia to diffuse large B-cell lymphoma with central nervous system involvement at diagnosis: a case report and literature review.
Chen H; Zhao D; Wang Z; Zhang W; Wang W
Clin Exp Med; 2023 Dec; 23(8):5473-5476. PubMed ID: 37921873
[TBL] [Abstract][Full Text] [Related]
65. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
66. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with Hodgkin disease. A report of two cases.
Rosales CM; Lin P; Mansoor A; Bueso-Ramos C; Medeiros LJ
Am J Clin Pathol; 2001 Jul; 116(1):34-40. PubMed ID: 11447749
[TBL] [Abstract][Full Text] [Related]
67. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
[TBL] [Abstract][Full Text] [Related]
68. An autopsy case of B-cell lymphoma associated with macroglobulinemia (IgM-k).
Umeno Y; Matsuishi E; Murakami Y; Nakao T; Miyamoto Y; Yoshitomi S; Irie K; Ohta Y
Fukuoka Igaku Zasshi; 1995 Jun; 86(6):293-7. PubMed ID: 7649519
[TBL] [Abstract][Full Text] [Related]
69. TCL1 expression patterns in Waldenström macroglobulinemia.
Lemal R; Bard-Sorel S; Montrieul L; Bay JO; Ravinet A; Ledoux-Pilon A; Cagnard N; Bailly S; Morel P; Charlotte F; Leleu X; Poulain S; Déchelotte PJ; Hermine O; Leblond V; Tournilhac O; Guièze R
Mod Pathol; 2016 Jan; 29(1):83-8. PubMed ID: 26493619
[TBL] [Abstract][Full Text] [Related]
70. Waldenström's macroglobulinemia is a biological syndrome which may occur during the evolution of different types of low grade B cell lymphoma.
Diebold J; Molina T; Tissier F; le Tourneau A; Audouin J
Leukemia; 1999 Oct; 13(10):1637-8. PubMed ID: 10516771
[No Abstract] [Full Text] [Related]
71. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
72. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
73. Angiogenesis in Waldenström's macroglobulinemia.
Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
[TBL] [Abstract][Full Text] [Related]
74. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Ngo HT; Azab AK; Farag M; Jia X; Melhem MM; Runnels J; Roccaro AM; Azab F; Sacco A; Leleu X; Anderson KC; Ghobrial IM
Clin Cancer Res; 2009 Oct; 15(19):6035-41. PubMed ID: 19755386
[TBL] [Abstract][Full Text] [Related]
75. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
76. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
77. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
78. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
[TBL] [Abstract][Full Text] [Related]
79. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
80. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
